|
GB0919431D0
(en)
*
|
2009-11-05 |
2009-12-23 |
Glaxosmithkline Llc |
Novel compounds
|
|
CN103154246B
(zh)
|
2010-05-14 |
2015-11-25 |
达那-法伯癌症研究所 |
用于治疗白血病的组合物和方法
|
|
CN103180318B
(zh)
|
2010-05-14 |
2017-05-10 |
达那-法伯癌症研究所 |
雄性避孕组合物以及使用方法
|
|
ES2606958T3
(es)
|
2010-05-14 |
2017-03-28 |
Dana-Farber Cancer Institute, Inc. |
Compuestos de tienotriazolodiazepina para tratar una neoplasia
|
|
AR084070A1
(es)
|
2010-12-02 |
2013-04-17 |
Constellation Pharmaceuticals Inc |
Inhibidores del bromodominio y usos de los mismos
|
|
WO2012075456A1
(en)
|
2010-12-02 |
2012-06-07 |
Constellation Pharmaceuticals |
Bromodomain inhibitors and uses thereof
|
|
GB201106750D0
(en)
*
|
2011-04-21 |
2011-06-01 |
Glaxosmithkline Llc |
Novel compounds
|
|
GB201106743D0
(en)
*
|
2011-04-21 |
2011-06-01 |
Glaxosmithkline Llc |
Novel compounds
|
|
GB201107325D0
(en)
|
2011-05-04 |
2011-06-15 |
Glaxosmithkline Llc |
Novel compounds
|
|
WO2012151512A2
(en)
|
2011-05-04 |
2012-11-08 |
Constellation Pharmaceuticals, Inc. |
Bromodomain inhibitors and uses thereof
|
|
WO2012174487A2
(en)
|
2011-06-17 |
2012-12-20 |
Constellation Pharmaceuticals, Inc. |
Bromodomain inhibitors and uses thereof
|
|
GB201114103D0
(en)
*
|
2011-08-17 |
2011-09-28 |
Glaxosmithkline Llc |
Novel compounds
|
|
WO2013027168A1
(en)
|
2011-08-22 |
2013-02-28 |
Pfizer Inc. |
Novel heterocyclic compounds as bromodomain inhibitors
|
|
WO2013033269A1
(en)
*
|
2011-08-29 |
2013-03-07 |
Coferon, Inc. |
Bioorthogonal monomers capable of dimerizing and targeting bromodomains and methods of using same
|
|
WO2013097052A1
(en)
|
2011-12-30 |
2013-07-04 |
Abbott Laboratories |
Bromodomain inhibitors
|
|
WO2013155695A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbott Laboratories |
Isoindolone derivatives
|
|
TWI602820B
(zh)
|
2012-06-06 |
2017-10-21 |
星宿藥物公司 |
溴域抑制劑及其用途
|
|
WO2013184878A1
(en)
|
2012-06-06 |
2013-12-12 |
Constellation Pharmaceuticals, Inc. |
Benzo [b] isoxazoloazepine bromodomain inhibitors and uses thereof
|
|
HK1208681A1
(en)
|
2012-06-12 |
2016-03-11 |
Abbvie Inc. |
Pyridinone and pyridazinone derivatives
|
|
EP2861255B1
(en)
|
2012-06-19 |
2019-10-09 |
The Broad Institute, Inc. |
Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy
|
|
JP2016507496A
(ja)
|
2012-12-21 |
2016-03-10 |
ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｃｏｒｐ． |
ブロモドメイン阻害剤としての新規複素環式化合物
|
|
EP2970312B1
(en)
|
2013-03-11 |
2017-11-15 |
The Regents of The University of Michigan |
Bet bromodomain inhibitors and therapeutic methods using the same
|
|
WO2014159392A1
(en)
|
2013-03-14 |
2014-10-02 |
Dana-Farber Cancer Institute, Inc. |
Bromodomain binding reagents and uses thereof
|
|
CN105189461B
(zh)
*
|
2013-03-14 |
2018-05-15 |
葛兰素史克知识产权第二有限公司 |
2,3-二取代的1-酰基-4-氨基-1,2,3,4-四氢喹啉衍生物和它们作为溴结构域抑制剂的用途
|
|
EA201591746A1
(ru)
|
2013-03-14 |
2016-08-31 |
КОНВЕРДЖЕН ЭлЭлСи |
Способы и композиции для ингибирования бромодомен-содержащих белков
|
|
US9670221B2
(en)
|
2013-03-14 |
2017-06-06 |
Glaxosmithkline Intellectual Property (No. 2) Limited |
Furopyridines as bromodomain inhibitors
|
|
EA035469B1
(ru)
|
2013-03-15 |
2020-06-22 |
Инсайт Холдингс Корпорейшн |
Трициклические гетероциклы как ингибиторы белков бэт
|
|
EA027139B1
(ru)
|
2013-04-26 |
2017-06-30 |
Бейджин, Лтд. |
Замещенные 5-(3,5-диметилизоксазол-4-ил)индолин-2-оны
|
|
KR102307566B1
(ko)
|
2013-06-21 |
2021-10-05 |
제니쓰 에피제네틱스 리미티드 |
신규한 바이사이클릭 브로모도메인 억제제
|
|
CN105473581B
(zh)
|
2013-06-21 |
2019-04-23 |
齐尼思表观遗传学有限公司 |
作为溴结构域抑制剂的新取代的双环化合物
|
|
HK1223364A1
(zh)
*
|
2013-06-28 |
2017-07-28 |
Abbvie Inc. |
布罗莫结构域抑制剂
|
|
AR096758A1
(es)
*
|
2013-06-28 |
2016-02-03 |
Abbvie Inc |
Inhibidores cristalinos de bromodominios
|
|
EP3019502B1
(en)
|
2013-07-08 |
2017-05-17 |
Incyte Holdings Corporation |
Tricyclic heterocycles as bet protein inhibitors
|
|
BR112016001457A2
(pt)
|
2013-07-25 |
2017-08-29 |
Dana Farber Cancer Inst Inc |
Inibidores de fatores de transcrição e usos dos mesmos
|
|
CA2919948C
(en)
|
2013-07-31 |
2020-07-21 |
Zenith Epigenetics Corp. |
Novel quinazolinones as bromodomain inhibitors
|
|
EP3290407B1
(en)
*
|
2013-10-18 |
2020-01-01 |
Celgene Quanticel Research, Inc |
Bromodomain inhibitors
|
|
US11446309B2
(en)
|
2013-11-08 |
2022-09-20 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors
|
|
BR122019007990B1
(pt)
*
|
2013-11-18 |
2021-05-04 |
Forma Therapeutics, Inc |
Composto, e, composição farmacêutica
|
|
RU2720237C2
(ru)
*
|
2013-11-18 |
2020-04-28 |
Форма Терапеутикс, Инк. |
Композиции, содержащие бензопиперазин, в качестве ингибиторов бромодоменов вет
|
|
US9399640B2
(en)
|
2013-11-26 |
2016-07-26 |
Incyte Corporation |
Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
|
|
US9108953B2
(en)
*
|
2013-11-26 |
2015-08-18 |
Gilead Sciences, Inc. |
Quinoline derivatives as bromodomain inhibitors
|
|
US9315501B2
(en)
|
2013-11-26 |
2016-04-19 |
Incyte Corporation |
Bicyclic heterocycles as BET protein inhibitors
|
|
US9309246B2
(en)
|
2013-12-19 |
2016-04-12 |
Incyte Corporation |
Tricyclic heterocycles as BET protein inhibitors
|
|
KR102394518B1
(ko)
*
|
2014-01-09 |
2022-05-06 |
오리온 코포레이션 |
브로모도메인 억제제로서의 비사이클릭 헤테로사이클릭 유도체
|
|
EA038715B1
(ru)
*
|
2014-01-24 |
2021-10-08 |
Селджен Квонтисел Рисёрч, Инк. |
Ингибиторы бромодомена
|
|
MX2016009974A
(es)
|
2014-01-31 |
2016-10-31 |
Dana Farber Cancer Inst Inc |
Derivados de diaminopirimidina bencensulfona y sus usos.
|
|
WO2015117083A1
(en)
|
2014-01-31 |
2015-08-06 |
Dana-Farber Cancer Institute, Inc. |
Diazepane derivatives and uses thereof
|
|
EP3099693A4
(en)
|
2014-01-31 |
2017-08-16 |
Dana-Farber Cancer Institute, Inc. |
Uses of diazepane derivatives
|
|
WO2015131113A1
(en)
|
2014-02-28 |
2015-09-03 |
Tensha Therapeutics, Inc. |
Treatment of conditions associated with hyperinsulinaemia
|
|
US9580430B2
(en)
|
2014-02-28 |
2017-02-28 |
The Regents Of The University Of Michigan |
9H-pyrimido[4,5-B]indoles and related analogs as BET bromodomain inhibitors
|
|
SMT202000133T1
(it)
|
2014-04-23 |
2020-05-08 |
Incyte Corp |
1h-pirrolo[2,3-c]piridin-7(6h)-oni e pirazolo[3,4-c]piridin-7(6h)-oni come inibitori di proteine bet
|
|
CN106687463B
(zh)
|
2014-06-20 |
2019-04-09 |
星座制药公司 |
一种乙酰胺类化合物的晶型
|
|
RU2017104897A
(ru)
|
2014-08-08 |
2018-09-10 |
Дана-Фарбер Кэнсер Инститьют, Инк. |
Производные диазепана и их применения
|
|
WO2016022970A1
(en)
|
2014-08-08 |
2016-02-11 |
Dana-Farber Cancer Institute, Inc. |
Dihydropteridinone derivatives and uses thereof
|
|
WO2016038120A1
(en)
*
|
2014-09-12 |
2016-03-17 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Tetrahydroquinoline derivatives as bromodomain inhibitors
|
|
JP6599979B2
(ja)
|
2014-09-15 |
2019-10-30 |
インサイト・コーポレイション |
Ｂｅｔタンパク質阻害剤として用いるための三環式複素環化合物
|
|
UA122130C2
(uk)
|
2014-10-27 |
2020-09-25 |
Тенша Терапеутікс, Інк. |
Інгібітори бромодомену
|
|
HK1245246A1
(zh)
|
2014-12-01 |
2018-08-24 |
恒翼生物医药科技(上海)有限公司 |
作为溴域抑制剂的取代吡啶酮
|
|
US10179125B2
(en)
|
2014-12-01 |
2019-01-15 |
Zenith Epigenetics Ltd. |
Substituted pyridines as bromodomain inhibitors
|
|
WO2016092375A1
(en)
|
2014-12-11 |
2016-06-16 |
Zenith Epigenetics Corp. |
Substituted heterocycles as bromodomain inhibitors
|
|
CN107406438B
(zh)
|
2014-12-17 |
2021-05-14 |
恒翼生物医药科技(上海)有限公司 |
溴结构域的抑制剂
|
|
EP3262045A1
(en)
|
2015-02-27 |
2018-01-03 |
The Regents of The University of Michigan |
9h-pyrimido [4,5-b]indoles as bet bromodomain inhibitors
|
|
GB201503720D0
(en)
|
2015-03-05 |
2015-04-22 |
Glaxosmithkline Ip No 2 Ltd |
Chemical compound
|
|
GB201504689D0
(en)
|
2015-03-19 |
2015-05-06 |
Glaxosmithkline Ip Dev Ltd |
Chemical compounds
|
|
GB201504694D0
(en)
*
|
2015-03-19 |
2015-05-06 |
Glaxosmithkline Ip Dev Ltd |
Covalent conjugates
|
|
TW201642860A
(zh)
*
|
2015-04-22 |
2016-12-16 |
塞爾基因定量細胞研究公司 |
布羅莫結構域抑制劑
|
|
US10702517B2
(en)
|
2015-04-22 |
2020-07-07 |
Celgene Quanticel Research, Inc. |
Bromodomain inhibitor
|
|
WO2016196065A1
(en)
|
2015-05-29 |
2016-12-08 |
Genentech, Inc. |
Methods and compositions for assessing responsiveness of cancers to bet inhibitors
|
|
CA2986441A1
(en)
|
2015-06-12 |
2016-12-15 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
|
WO2016203335A1
(en)
|
2015-06-18 |
2016-12-22 |
Pfizer Inc. |
Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
|
|
AU2016283020A1
(en)
|
2015-06-26 |
2018-01-04 |
Tensha Therapeutics, Inc. |
Treatment of nut midline carcinoma
|
|
BR112018002550A2
(en)
|
2015-08-10 |
2018-09-18 |
Dana-Farber Cancer Institute, Inc. |
inhibitor resistance mechanism
|
|
MA43940A
(fr)
|
2015-09-02 |
2018-12-12 |
Glaxosmithkline Ip No 2 Ltd |
Dicarboxamide de pyridinone utilisé comme inhibiteur de bromodomaine
|
|
US11306105B2
(en)
|
2015-09-11 |
2022-04-19 |
Dana-Farber Cancer Institute, Inc. |
Cyano thienotriazolodiazepines and uses thereof
|
|
RU2018112953A
(ru)
|
2015-09-11 |
2019-10-14 |
Дана-Фарбер Кэнсер Инститьют, Инк. |
Ацетамидтиенотриазолодиазепины и пути их применения
|
|
EP3353162A1
(en)
|
2015-09-22 |
2018-08-01 |
Glaxosmithkline Intellectual Property (No. 2) Limited |
Pyridinone dicarboxamide for use as bromodomain inhibitors
|
|
BR112018006545A2
(pt)
|
2015-10-05 |
2018-10-16 |
Glaxosmithkline Ip No 2 Ltd |
?composto, composição farmacêutica, combinação, uso de um composto, e, método para tratamento de uma doença ou condição?
|
|
WO2017075377A1
(en)
|
2015-10-29 |
2017-05-04 |
Incyte Corporation |
Amorphous solid form of a bet protein inhibitor
|
|
CR20180336A
(es)
|
2015-11-25 |
2018-08-06 |
Dana Farber Cancer Inst Inc |
Inhibidores de bromodominio bivalentes y usos de los mismos
|
|
CA3014644A1
(en)
|
2016-02-15 |
2017-08-24 |
The Regents Of The University Of Michigan |
Fused 1,4-oxazepines and related analogs as bet bromodomain inhibitors
|
|
EP3440082A1
(en)
|
2016-04-06 |
2019-02-13 |
The Regents of The University of Michigan |
Monofunctional intermediates for ligand-dependent target protein degradation
|
|
AU2017246452C1
(en)
|
2016-04-06 |
2021-06-03 |
The Regents Of The University Of Michigan |
MDM2 protein degraders
|
|
TW201802076A
(zh)
|
2016-04-07 |
2018-01-16 |
葛蘭素史密斯克藍智慧財產權有限公司 |
化合物
|
|
ES2840848T3
(es)
|
2016-04-07 |
2021-07-07 |
Glaxosmithkline Ip No 2 Ltd |
Derivados de piridilo como inhibidores de bromodominio
|
|
AU2017250076B2
(en)
|
2016-04-12 |
2021-07-22 |
The Regents Of The University Of Michigan |
Bet protein degraders
|
|
AU2017251537B2
(en)
|
2016-04-15 |
2020-10-08 |
Abbvie Inc. |
Bromodomain inhibitors
|
|
KR20190006567A
(ko)
|
2016-05-24 |
2019-01-18 |
글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 |
브로모도메인 억제제로서의 피리딘 디카르복사미드 유도체
|
|
WO2017205536A2
(en)
*
|
2016-05-24 |
2017-11-30 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
|
CN109715625B
(zh)
|
2016-06-20 |
2022-04-19 |
因赛特公司 |
Bet抑制剂的结晶固体形式
|
|
GB201614939D0
(en)
|
2016-09-02 |
2016-10-19 |
Glaxosmithkline Ip Dev Ltd |
Crystalline hydrate
|
|
GB201614934D0
(en)
|
2016-09-02 |
2016-10-19 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Chemical compounds
|
|
GB201614940D0
(en)
|
2016-09-02 |
2016-10-19 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Chemical compounds
|
|
CA3036834A1
(en)
|
2016-09-13 |
2018-03-22 |
The Regents Of The University Of Michigan |
Fused 1,4-oxazepines as bet protein degraders
|
|
ES2857743T3
(es)
|
2016-09-13 |
2021-09-29 |
Univ Michigan Regents |
1,4-diazepinas fusionadas como degradadores de proteína BET
|
|
CN110099685A
(zh)
*
|
2016-10-20 |
2019-08-06 |
赛尔基因光迪斯研究公司 |
溴结构域抑制剂
|
|
US11028051B2
(en)
*
|
2016-12-13 |
2021-06-08 |
St. Jude Children's Research Hospital |
Tetrahydroquinoline-based bromodomain inhibitors
|
|
EP3577120A1
(en)
|
2017-02-03 |
2019-12-11 |
The Regents of The University of Michigan |
Fused 1,4-diazepines as bet bromodomain inhibitors
|
|
GB201716374D0
(en)
*
|
2017-10-06 |
2017-11-22 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Compounds
|
|
GB201703282D0
(en)
|
2017-03-01 |
2017-04-12 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Compounds
|
|
JOP20190192A1
(ar)
*
|
2017-03-01 |
2019-08-08 |
Glaxosmithkline Ip No 2 Ltd |
مشتقات بيرازول بوصفها مثبطات برومودومين
|
|
US11267822B2
(en)
|
2017-09-13 |
2022-03-08 |
The Regents Of The University Of Michigan |
BET bromodomain protein degraders with cleavable linkers
|
|
GB201716392D0
(en)
|
2017-10-06 |
2017-11-22 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Compounds
|
|
GB201716369D0
(en)
|
2017-10-06 |
2017-11-22 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Compounds
|
|
GB201814167D0
(en)
|
2018-08-31 |
2018-10-17 |
Glaxosmithkline Ip No 2 Ltd |
Compounds
|
|
TWI882964B
(zh)
|
2018-09-13 |
2025-05-11 |
大陸商恒翼生物醫藥（上海）股份有限公司 |
Bet 溴結構域(bromodomain)抑制劑之固體形式之製備方法
|
|
TWI816880B
(zh)
*
|
2018-09-13 |
2023-10-01 |
大陸商恒翼生物醫藥（上海）股份有限公司 |
治療前列腺癌之組合療法
|
|
WO2021175432A1
(en)
|
2020-03-04 |
2021-09-10 |
Boehringer Ingelheim International Gmbh |
Method for administration of an anti cancer agent
|
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
|
US20240316061A1
(en)
|
2021-09-17 |
2024-09-26 |
Institut Curie |
Bet inhibitors for treating pab1 deficient cancer
|
|
CA3255932A1
(en)
|
2022-04-19 |
2023-10-26 |
Nuevolution A/S |
ACTIVE COMPOUNDS AGAINST BROMODOMAINS
|
|
WO2025049555A1
(en)
|
2023-08-31 |
2025-03-06 |
Oerth Bio Llc |
Compositions and methods for targeted inhibition and degradation of proteins in an insect cell
|